Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 271

1.

A Randomized Trial of Oral and Transdermal Rivastigmine for Postural Instability in Parkinson Disease Dementia.

McDonald J, Pourcher E, Nadeau A, Corbeil P.

Clin Neuropharmacol. 2018 May/Jun;41(3):87-93. doi: 10.1097/WNF.0000000000000275.

PMID:
29537978
2.

Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.

Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, Windfeld K, Raket LL, Cummings JL.

JAMA. 2018 Jan 9;319(2):130-142. doi: 10.1001/jama.2017.20373.

3.

Transdermal rivastigmine for HIV-associated cognitive impairment: A randomized pilot study.

Muñoz-Moreno JA, Prats A, Moltó J, Garolera M, Pérez-Álvarez N, Díez-Quevedo C, Miranda C, Fumaz CR, Ferrer MJ, Clotet B; TRIANT-TE Study Group.

PLoS One. 2017 Aug 30;12(8):e0182547. doi: 10.1371/journal.pone.0182547. eCollection 2017.

4.

Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.

Park KW, Kim EJ, Han HJ, Shim YS, Kwon JC, Ku BD, Park KH, Yi HA, Kim KK, Yang DW, Lee HW, Kang H, Kwon OD, Kim S, Lee JH, Chung EJ, Park SW, Park MY, Yoon B, Kim BC, Seo SW, Choi SH.

PLoS One. 2017 Aug 7;12(8):e0182123. doi: 10.1371/journal.pone.0182123. eCollection 2017.

5.

Bioequivalence Study of Rivastigmine 6 mg Capsules (Single Dose) in Healthy Volunteers.

Abhyankar D, Shedage A, Gole M, Raut P.

Am J Alzheimers Dis Other Demen. 2017 Sep;32(6):360-366. doi: 10.1177/1533317517712890. Epub 2017 Jul 3.

PMID:
28670911
6.

Pharmacological Manipulation of Cortical Inhibition in the Dorsolateral Prefrontal Cortex.

Salavati B, Rajji TK, Zomorrodi R, Blumberger DM, Chen R, Pollock BG, Daskalakis ZJ.

Neuropsychopharmacology. 2018 Jan;43(2):354-361. doi: 10.1038/npp.2017.104. Epub 2017 May 29.

7.

Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.

Campbell NL, Perkins AJ, Gao S, Skaar TC, Li L, Hendrie HC, Fowler N, Callahan CM, Boustani MA.

J Am Geriatr Soc. 2017 Jul;65(7):1497-1504. doi: 10.1111/jgs.14827. Epub 2017 Mar 14.

8.

Effect of Rivastigmine Augmentation in Treatment of Male Patients With Combat-Related Chronic Posttraumatic Stress Disorder: A Randomized Controlled Trial.

Rezaei Ardani A, Hosseini G, Fayyazi Bordbar MR, Talaei A, Mostafavi Toroghi H.

J Clin Psychopharmacol. 2017 Feb;37(1):54-60. doi: 10.1097/JCP.0000000000000624.

PMID:
27930500
9.

Absolute bioavailability and safety of a novel rivastigmine nasal spray in healthy elderly individuals.

Morgan TM, Soh B.

Br J Clin Pharmacol. 2017 Mar;83(3):510-516. doi: 10.1111/bcp.13133. Epub 2016 Oct 26.

11.

[Rivastigmine and Parkinson's disease without dementia : Impact on gait stability and frequency of falling].

Amadori K.

Z Gerontol Geriatr. 2016 Oct;49(7):662-663. German. No abstract available.

PMID:
27599816
12.

Rivastigmine patch reduces the incidence of postoperative delirium in older patients with cognitive impairment.

Youn YC, Shin HW, Choi BS, Kim S, Lee JY, Ha YC.

Int J Geriatr Psychiatry. 2017 Oct;32(10):1079-1084. doi: 10.1002/gps.4569. Epub 2016 Aug 26.

PMID:
27561376
14.
15.

Safety and efficacy of rivastigmine in children with Down syndrome: A double blind placebo controlled trial.

Spiridigliozzi GA, Hart SJ, Heller JH, Schneider HE, Baker JA, Weadon C, Capone GT, Kishnani PS.

Am J Med Genet A. 2016 Jun;170(6):1545-55. doi: 10.1002/ajmg.a.37650. Epub 2016 Apr 8.

PMID:
27061338
16.

Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).

Zhang ZX, Hong Z, Wang YP, He L, Wang N, Zhao ZX, Zhao G, Shang L, Weisskopf M, Callegari F, Strohmaier C.

CNS Neurosci Ther. 2016 Jun;22(6):488-96. doi: 10.1111/cns.12521. Epub 2016 Mar 25.

17.

Effects of rivastigmine on visual attention in subjects with amnestic mild cognitive impairment: A serial functional MRI activation pilot-study.

Bokde AL, Cavedo E, Lopez-Bayo P, Lista S, Meindl T, Born C, Galluzzi S, Faltraco F, Dubois B, Teipel SJ, Reiser M, Möller HJ, Hampel H.

Psychiatry Res Neuroimaging. 2016 Mar 30;249:84-90. doi: 10.1016/j.pscychresns.2016.01.018. Epub 2016 Jan 18.

PMID:
26851974
18.

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial.

Henderson EJ, Lord SR, Brodie MA, Gaunt DM, Lawrence AD, Close JC, Whone AL, Ben-Shlomo Y.

Lancet Neurol. 2016 Mar;15(3):249-58. doi: 10.1016/S1474-4422(15)00389-0. Epub 2016 Jan 13.

19.

Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease.

Isaacson RS, Ferris S, Velting DM, Meng X.

Am J Alzheimers Dis Other Demen. 2016 May;31(3):270-7. doi: 10.1177/1533317515603687. Epub 2015 Sep 14.

PMID:
26371345
20.

Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients.

Li Z, Yu Z, Zhang J, Wang J, Sun C, Wang P, Zhang J.

Eur Neurol. 2015;74(1-2):86-91. doi: 10.1159/000438824. Epub 2015 Aug 20.

PMID:
26288230

Supplemental Content

Loading ...
Support Center